Elina Urpilainen1, Reetta Arima2, Peeter Karihtala3, Ulla Puistola4, Anne Ahtikoski5. 1. Department of Obstetrics and Gynaecology, PEDEGO Research Unit, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland; elina.urpilainen@gmail.com. 2. Department of Obstetrics and Gynaecology, Central Finland Central Hospital, Jyväskylä, Finland. 3. Department of Oncology, University of Helsinki and Helsinki University Comprehensive Cancer Center, Helsinki, Finland. 4. Department of Obstetrics and Gynaecology, PEDEGO Research Unit, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland. 5. Department of Pathology, Cancer and Translational Medicine Research Unit, Oulu University Hospital and University of Oulu, Oulu, Finland.
Abstract
BACKGROUND/AIM: Preclinical studies on metformin use and endometrial cancer have been promising but epidemiological studies have reported variable results. This study aimed to assess if metformin use is associated with endometrial cancer aggressiveness and survival in women with type 2 diabetes (T2D). PATIENTS AND METHODS: This retrospective hospital-based cohort consisted of women with T2D who were treated for endometrial cancer at the Oulu University Hospital, Finland, between 2007 and 2014. RESULTS: The sample size was 121 patients: 58 metformin users and 63 metformin non-users. Intriguingly, type 2 histology, deep myometrial invasion and the presence of lymphovascular invasion were more common in the metformin user group. However, metformin use showed no association with overall survival and progression-free survival. CONCLUSION: Metformin use was associated with poorer prognostic factors in endometrial cancer patients with T2D.
BACKGROUND/AIM: Preclinical studies on metformin use and endometrial cancer have been promising but epidemiological studies have reported variable results. This study aimed to assess if metformin use is associated with endometrial cancer aggressiveness and survival in women with type 2 diabetes (T2D). PATIENTS AND METHODS: This retrospective hospital-based cohort consisted of women with T2D who were treated for endometrial cancer at the Oulu University Hospital, Finland, between 2007 and 2014. RESULTS: The sample size was 121 patients: 58 metformin users and 63 metformin non-users. Intriguingly, type 2 histology, deep myometrial invasion and the presence of lymphovascular invasion were more common in the metformin user group. However, metformin use showed no association with overall survival and progression-free survival. CONCLUSION:Metformin use was associated with poorer prognostic factors in endometrial cancerpatients with T2D.
Authors: Masuma Khatun; Elina Urpilainen; Anne Ahtikoski; Riikka K Arffman; Annukka Pasanen; Ulla Puistola; Juha S Tapanainen; Leif C Andersson; Ralf Butzow; Mikko Loukovaara; Terhi T Piltonen Journal: Pathol Oncol Res Date: 2021-09-28 Impact factor: 3.201